U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.The Dow traded up 0.06% to 46,299.96 while the NASDAQ climbed 0.52% to 22,639.61. The S&P 500 also rose, gaining, 0.33% to 6,666.08.Check This Out: Top 2 Financial Stocks That May Collapse This QuarterLeading and Lagging SectorsCommunication services shares jumped by 1.6% on Wednesday.In trading on Wednesday, health care stocks rose by 0.1%.Top HeadlineAbbott Laboratories (NYSE:ABT) stock ...

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.The Dow traded up 0.06% to 46,299.96 while the NASDAQ climbed 0.52% to 22,639.61. The S&P 500 also rose, gaining, 0.33% to 6,666.08.Check This Out: Top 2 Financial Stocks That May Collapse This QuarterLeading and Lagging SectorsCommunication services shares jumped by 1.6% on Wednesday.In trading on Wednesday, health care stocks rose by 0.1%.Top HeadlineAbbott Laboratories (NYSE:ABT) stock ...

Core Viewpoint - U.S. stock markets showed a mixed but largely positive performance driven by strong corporate earnings, particularly in the financial sector, and expectations for a Federal Reserve interest rate cut, despite ongoing U.S.-China trade tensions and a government shutdown [1][9][10] Market Indexes and Afternoon Trading Activity - Major U.S. stock indexes displayed resilience with the S&P 500 up 0.1%, Nasdaq Composite up 0.3%, and Dow Jones Industrial Average down 0.1% in afternoon trading [2] - Earlier in the day, the Dow rose by 351 points (0.8%), S&P 500 increased by 1%, and Nasdaq Composite jumped by 1.2% during a broad rally [2] Sector Performance - The financial sector was a key driver of positive sentiment, bolstered by strong third-quarter earnings, although some financial stocks softened in afternoon trading [3] - The PHLX Semiconductor Index surged by 2.5%, fueled by optimism regarding AI spending, while technology stocks showed signs of recovery after previous weakness [3] Major Stock News and Corporate Announcements - Bank of America and Morgan Stanley reported strong third-quarter results, with profit jumps of 23% and 45% respectively, leading to share increases of approximately 3.5% and 5% [4] - Other financial institutions like JPMorgan Chase, Citigroup, Goldman Sachs, and Wells Fargo also exceeded analysts' estimates, contributing to sector strength [4] - In the technology sector, ASML Holding gained 2% on better-than-expected bookings, while Advanced Micro Devices soared 6.5% following a deal with Oracle [5] Upcoming Market Events - Investors are focused on the Federal Reserve's upcoming meeting on October 28-29, where a potential interest rate cut below 4% is anticipated [6] - Economic data releases, including the Consumer Price Index (CPI) and Producer Price Index (PPI), are also being monitored, although some have been delayed due to the government shutdown [7] Market Sentiment and Outlook - Overall market sentiment reflects a mix of optimism from strong corporate earnings and caution due to ongoing trade tensions and the government shutdown [9][10] - Hopes for a Federal Reserve rate cut are contributing to positive investor sentiment, potentially stimulating economic growth [9]

Market Performance - Stocks are climbing, with the S&P 500 rising 0.8%, the Dow Jones Industrial Average up 254 points (0.5%), and the Nasdaq composite increasing by 1.1% [1] - Tech stocks, particularly ASML, Broadcom, and Nvidia, contributed significantly to the market gains [5][7] Earnings Reports - UBS noted that early-reporting companies have a good relationship with the overall earnings season, with 80% beating sales estimates and over 70% beating earnings-per-share estimates [2] - The median company is beating earnings by 2.2%, lower than the historical average of 3.5% [2] - Bank of America reported a profit stronger than expected, leading to a 5.2% increase in its stock [7] - Morgan Stanley's stock rose 6.4% after reporting better-than-expected profits, following strong results from JPMorgan Chase and Wells Fargo [8] Economic Indicators - Corporate profit reports are under increased scrutiny as investors seek insights into the U.S. economy's health, especially with delays in key economic updates due to the government shutdown [10] - The Federal Reserve cut its main interest rate last month, with indications of potential further cuts to support the job market [11] Industry Trends - ASML expects its revenue for 2025 to be 15% above last year's, indicating strong growth in the semiconductor industry [5] - There is positive momentum in AI investments, despite concerns about a potential bubble similar to the 2000 dot-com frenzy [6] Commodity Market - Gold prices rose 1.3% to over $4,200 per ounce, reflecting a nearly 60% increase for the year as investors seek safe-haven assets amid economic uncertainties [13]

Core Insights - Abbott Laboratories' shares fell 3% following a less-than-stellar Q3 performance, with revenue rising 6.9% to $11.37 billion, missing the $11.4 billion consensus estimate [1] - Organic sales, excluding Covid testing, increased by 7.5%, surpassing the 5.9% estimate [1] - Adjusted earnings per share (EPS) rose 7.4% to $1.30, aligning with expectations [1] Financial Performance - Q3 sales in three of Abbott's four main operating segments fell short of expectations, marking the second consecutive disappointing quarter [1] - Medical Devices sales grew 12.5% organically, driven by strong performance in diabetes care and other segments [1] - Established Pharmaceuticals saw a 7.1% organic increase, while emerging markets exceeded $1 billion in sales, growing 11.1% organically [1] - Diagnostics sales declined 7.8% organically, primarily due to a nearly 28% drop in rapid diagnostics [1] Market Position and Strategy - Abbott's management tightened their full-year EPS outlook to a range of $5.12 to $5.18, consistent with consensus estimates [1] - The company continues to expect full-year organic sales growth of 7.5% to 8%, excluding Covid testing [1] - Concerns were raised regarding Abbott's exposure to China's sluggish healthcare sector, prompting discussions about portfolio adjustments [1] Segment Analysis - Nutrition sales grew 4% year over year, with adult segment sales increasing 5.4% organically, led by products like Ensure and Glucerna [2] - The point of care diagnostics segment saw nearly 8% organic growth, highlighting the adoption of new tests [1] - Abbott's ongoing litigation regarding its specialized formula for premature infants remains a concern, although management stands by the product [1]

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday's key moments. 1. The stock market is higher Wednesday as a rollout of better-than-expected earnings overshadowed investor concerns on intensifying U.S.- China trade talks. President Donald Trump 's latest threat to China on Tuesday afternoon derailed the S & P 500's rally attempt. That failed comeback had been fueled by earlier comments from Fed Chair Jerome Powell sugges ...

Core Insights - Abbott Laboratories (ABT) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.30, matching the Zacks Consensus Estimate and reflecting a 7.4% increase from the prior year [1][8] - Total revenues for the quarter were $11.37 billion, up 6.9% year over year, but slightly missing the Zacks Consensus Estimate by 0.24% [2][8] Revenue Breakdown - Established Pharmaceuticals segment sales increased by 7.5% to $1.51 billion, with organic sales in emerging markets growing by 11.1% [3] - Medical Devices segment sales rose 14.8% to $5.45 billion, driven by strong growth in Diabetes Care and other areas [4] - Nutrition sales grew by 4.2% to $2.15 billion, with Adult Nutrition benefiting from strong global brand performance [5][6] - Diagnostics sales declined by 6.6% to $2.25 billion, with organic sales ex-COVID rising by 0.4% [6] Margin and Expense Analysis - Gross profit increased by 6% to $6.29 billion, but gross margin contracted by 46 basis points to 55.4% [9] - Selling, general and administrative expenses rose by 5.4% to $3.05 billion, while research and development expenses increased by 7.4% to $766 million [10] Financial Guidance - For the full year, Abbott expects adjusted diluted EPS in the range of $5.12 to $5.18, reaffirming previous guidance [11] - Full-year organic sales growth, excluding COVID-19 testing-related sales, is projected to be between 7.5% and 8.0% [12] Market Position and Developments - Abbott's third-quarter performance was mixed, with earnings exceeding estimates while revenues fell short [13] - Notable developments include regulatory approval in Japan for TriClip and CE Mark for the Navitor TAVI system [14]

By Christy Santhosh and Kamal Choudhury (Reuters) -Abbott missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses outweighed robust demand for its medical devices. The company had flagged volatility in the businesses as it navigates a sharp decline in COVID-19 testing demand, new U.S. tariffs, and a freeze on foreign aid by President Donald Trump's administration. The diagnostics division is also facing pricing pressure from China's procurem ...

Market Overview - Major stock indices have shown strong upward movement, with the Nasdaq up 296.91 points (1.3%), S&P 500 up 67.24 points (1.0%), and Dow up 290.89 points (0.6%) [1] Company Earnings - Morgan Stanley's shares surged by 7.2% after reporting better than expected third quarter results [2] - Bank of America also saw a 5.2% increase in shares following third quarter results that exceeded analyst estimates [2] - ASML reported mixed third quarter results but expects 2026 total net sales to exceed 2025, leading to significant strength in its U.S.-listed shares [3] - Abbott Laboratories faced pressure on its shares after reporting weaker than expected third quarter revenues [3] Economic Indicators - The New York Fed's general conditions index rose to a positive 10.7 in October, a significant turnaround from a negative 8.7 in September, indicating growth [5] Sector Performance - Gold stocks have risen sharply, with the NYSE Arca Gold Bugs Index up 3.3% to a record intraday high [6] - Computer hardware and semiconductor stocks also showed substantial strength, with the NYSE Arca Computer Hardware Index and the Philadelphia Semiconductor Index up 3.3% and 2.9%, respectively [6] - Brokerage, networking, and telecom stocks are experiencing significant strength, moving higher along with most major sectors [7] International Markets - In the Asia-Pacific region, stocks moved mostly higher, with Japan's Nikkei 225 Index up 1.8% and China's Shanghai Composite Index up 1.2% [8] - European markets showed mixed performance, with the U.K.'s FTSE 100 Index down 0.1%, while the German DAX Index remained stable and the French CAC 40 Index rose by 2.2% [8] Bond Market - Treasuries are showing modest strength, with the yield on the benchmark ten-year note down by 1.3 basis points at 4.009% [9]

医疗设备制造商雅培(ABT.US)跌超2.6%，报129.22美元。消息面上，雅培公布第三季度业绩，营收为 113.7亿美元，略低于分析师平均预期的114亿美元，每股收益为1.3美元，符合分析师预期。雅培预计全 年每股收益将介于5.12至5.18美元之间，之前预期为5.1至5.2美元。(格隆汇) ...